These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 9613915)
41. Lipid-lowering with statins and fibrinolytic parameters. Jovin IS; Heidinger K; Taborski U; Muller-Berghaus G Eur Heart J; 1997 Sep; 18(9):1516. PubMed ID: 9458463 [No Abstract] [Full Text] [Related]
42. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430 [TBL] [Abstract][Full Text] [Related]
43. Effective use of statins to prevent coronary heart disease. Crouch MA Am Fam Physician; 2001 Jan; 63(2):309-20, 323-4. PubMed ID: 11201696 [TBL] [Abstract][Full Text] [Related]
44. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Rackley CE Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986 [TBL] [Abstract][Full Text] [Related]
45. Modulation of the inflammatory process by statins. Crisby M Timely Top Med Cardiovasc Dis; 2005 Mar; 9():E3. PubMed ID: 15824762 [TBL] [Abstract][Full Text] [Related]
46. C-reactive protein levels and outcomes after statin therapy. Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E; N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109 [TBL] [Abstract][Full Text] [Related]
47. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
48. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Ray KK; Cannon CP; Ganz P Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675 [TBL] [Abstract][Full Text] [Related]
49. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Smith DG; McBurney CR Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031 [TBL] [Abstract][Full Text] [Related]
56. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Brandle M; Davidson MB; Schriger DL; Lorber B; Herman WH Diabetes Care; 2003 Jun; 26(6):1796-801. PubMed ID: 12766112 [TBL] [Abstract][Full Text] [Related]
57. Managing dyslipidemia in the high-risk patient. Stein EA Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720 [TBL] [Abstract][Full Text] [Related]
58. [LDL cholesterol in normal range. The lower the better? Implications of the GREACE study]. März W MMW Fortschr Med; 2003 Dec; 145(50):46-9. PubMed ID: 14963971 [TBL] [Abstract][Full Text] [Related]
59. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]